139 results
8-K
EX-99.1
ALKS
Alkermes plc
24 Jul 24
Alkermes plc Reports Second Quarter 2024 Financial Results
7:05am
for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical
and preclinical candidates
8-K
EX-99.1
ALKS
Alkermes plc
1 May 24
Alkermes plc Reports First Quarter 2024 Financial Results
7:05am
for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates
8-K
EX-99.1
ehslgw9hcfhycs2 qjye
9 Apr 24
Regulation FD Disclosure
7:09am
8-K
EX-99.1
t9lh74th0w74nshu1k
7 Mar 24
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
7:09am
8-K
EX-99.1
r58q wclm
15 Feb 24
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
rc3ow6kbbwo
8 Jan 24
Regulation FD Disclosure
7:00am
8-K
EX-99.1
6c1a xf8i
14 Dec 23
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
6:13am
8-K
EX-99.1
h4fnbx7nw96iclns
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-99.2
y7mbktb zr6
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-99.1
1vijbg0a wmtkq7j
31 Oct 23
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
5:18pm
8-K
EX-99.1
pcn52s5x
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
8-K
EX-99.1
59z2rb5b
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
8-K
EX-99.1
6vi3zcd9fcki8c4
30 Aug 23
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
7:14am